Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.
The WHO has delayed its controversial EB 124/14 amendment that would, according to some groups, broaden the organisation’s definition of “counterfeit” from its current focus on patient health to include infringements of intellectual property.
AstraZeneca has started construction a €30 million tablet
manufacturing plant in Egypt that could form a springboard for an
expansion into emerging markets.
